Ruxolitinib is a highly potent JAK2 inhibitor approved for the treatment of myelofibrosis (idiopathic or post-polycythemia vera or post-essential thrombocythemia) and, more recently, for polycythemia vera with an inadequate response to or intolerant of hydroxyurea. The most common adverse events of ruxolitinib include immunosuppression with an increased risk of reactivation of silent infections and increased non-melanoma skin cancer. The known neurological side effects of ruxolitinib are dizziness and headache, but no neurological paroxysmal episodes have been recorded. This report deals with an 80-year-old outpatient woman with polycythemia vera turned into myelofibrosis who experienced neurological episodes of hypoesthesia and weakness of right arm and leg during ruxolitinib treatment.

Unexpected Neurological Symptoms of Ruxolitinib: A Case Report / F. Furia, M.P. Canevini, A.B. Federici, M.C. Carraro. - In: JOURNAL OF HEMATOLOGY. - ISSN 1927-1212. - 9:4(2020 Dec), pp. 137-139. [10.14740/jh642]

Unexpected Neurological Symptoms of Ruxolitinib: A Case Report

M.P. Canevini
Secondo
;
A.B. Federici
Penultimo
;
2020

Abstract

Ruxolitinib is a highly potent JAK2 inhibitor approved for the treatment of myelofibrosis (idiopathic or post-polycythemia vera or post-essential thrombocythemia) and, more recently, for polycythemia vera with an inadequate response to or intolerant of hydroxyurea. The most common adverse events of ruxolitinib include immunosuppression with an increased risk of reactivation of silent infections and increased non-melanoma skin cancer. The known neurological side effects of ruxolitinib are dizziness and headache, but no neurological paroxysmal episodes have been recorded. This report deals with an 80-year-old outpatient woman with polycythemia vera turned into myelofibrosis who experienced neurological episodes of hypoesthesia and weakness of right arm and leg during ruxolitinib treatment.
Myelofibrosis; Polycythemia vera; Ruxolitinib
Settore MED/39 - Neuropsichiatria Infantile
Article (author)
File in questo prodotto:
File Dimensione Formato  
642-3426-2-PB.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 327.45 kB
Formato Adobe PDF
327.45 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/827256
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact